 MONMOUTH JUNCTION, N.J., July 6, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO announces the full approval of its Investigational Device Exemption IDE application to conduct the pivotal STAR-T Safe and Timely Antithrombotic Removal Ticagrelor double-blind, randomized, controlled trial RCT in the United States to support FDA regulatory clearance. 